NT-proBNP in practice: From chemistry to medicine;NT-proBNP en pratique « De la biologie à la Clinique »

Annales de Biologie Clinique

Volumn 67, Issue 3, 2009, Pages 255-271

  Jourdain, P ^a   Lefevre G ^b   Oddoze, C ^c   Sapin, V ^d   Dievart, F ^e   Jondeau, G ^f   Meune, C ^g   Galinier, M ^h  

^a CENTRE HOSPITALIER RENÉ DUBOS   (France)

^b HÔPITAL TENON   (France)

^c TIMONE HOSPITAL   (France)

^d UNIVERSITY HOSPITAL OF CLERMONT FERRAND   (France)

^e Clinique Villette   (France)

^f BICHAT HOSPITAL   (France)

^g Institut Cochin   (France)

^h CHU RANGUEIL   (France)

Author keywords

Heart failure; Natriuretic peptides; NT proBNP

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; PEPTIDE FRAGMENT; PRO BRAIN NATRIURETIC PEPTIDE (1 76); PRO-BRAIN NATRIURETIC PEPTIDE (1-76); PROTEIN PRECURSOR;

ACUTE CORONARY SYNDROME; ACUTE DISEASE; BLOOD; DRUG STABILITY; HEART FAILURE; HUMAN; METABOLISM; REVIEW; SENSITIVITY AND SPECIFICITY;

ACUTE CORONARY SYNDROME; ACUTE DISEASE; DRUG STABILITY; HEART FAILURE; HUMANS; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PROTEIN PRECURSORS; SENSITIVITY AND SPECIFICITY;

EID: 70149114764     PISSN: 00033898     EISSN: 19506112     Source Type: Journal    
DOI: 10.1684/abc.2009.0331     Document Type: Article

References (99)

1. Januzzi Jr. JL, Richards MR. An international consensus statement regarding amino-terminal Pro-B-type natriuretic peptide testing : the international NT-proBNP consensus panel. Am J Cardiol 2008; 101 (Suppl) : S1-96.
2. Hall C. Essential biochemistry and physiology of (NT-pro)BNP Eur. J Heart Fail 2004; 6 : 257-60.
3. Sudoh T, Kangawa K, Minamino N. A new natriuretic peptide in porcine brain. Nature 1988; 332 : 78-82.
4. Martinez-Rumayor A, Richards AM, Burnett JC, Januzzi JL. Biology of the natriuretic peptides. Am J Cardiol 2008; 101 : 3-8.
5. Gerbes AL, Dagnino L, Nguyen T, Nemer M. Transcription of brain natriuretic peptide and atrial natriuretic peptide genes in human tissues. J Clin Endocrinol Metab 1994; 78 : 1307-11.
6. Chen HH, Burnett JC. The natriuretic peptides in heart failure : diagnostic and therapeutic potentials. Proc Assoc Am Physicians 1999; 111 : 406-16.
7. Hall C. NT-ProBNP : the mechanism behind the marker. J Card Fail 2005; 11 (5 Suppl.) : S81-3.
8. Goetze JP, Gore A, Moller CH. Acute myocardial hypoxia increases BNP gene expression. FASEB J 2004; 18 : 1928-30.
9. Seilhamer JJ, Arfsten A, Miller JA, Lundquist P, Scarborough RM, Lewicki JA, et al. Human and canine gene homologs of porcine brain natriuretic peptide. Biochem Biophys Res Commun 1989; 165 : 650-8. (Pubitemid 20025571)
10. Rehemudula D, Nakayama T, Soma M, Takahashi Y, Uwabo J, Sato M, et al. Structure of the type B human natriuretic peptide receptor gene and association of a novel microsatellite polymorphism with essential hypertension. Circ Res 1999; 84 : 605-10.
11. Kroll MH, Twomey PJ, Srisawasdi P. Using the single-compartment ratio model to calculate half-life, NT-proBNP as an example. Clin Chim Acta 2007; 380 : 197-202.
12. Bentzen H, Pedersen RS, Pedersen HB, Nyvad O, Pedersen EB. Abnormal rhythmic oscillations of atrial natriuretic peptide and brain natriuretic peptide in heart failure. Clin Sci (Lond) 2003; 104 : 303-12.
13. Hogenhuis J, Voors AA, Jaarsma T, Hillege HL, Boomsma F, van Veldhuisen DJ. Influence of age on natriuretic peptides in patients with chronic heart failure : a comparison between ANP/NT-ANP and BNP/NT-proBNP. Eur J Heart Fail 2005; 7 : 81-6.
14. Wu AH. Serial testing of B-type natriuretic peptide and NTpro-BNP for monitoring therapy of heart failure : the role of biologic variation in the interpretation of results. Am Heart J 2006; 152 : 828-34.
15. Liang F, O'Rear J, Schellenberger U, Tai L, Lasecki M, Schreiner GF, et al. Evidence for functional heterogeneity of circulating Btype natriuretic peptide. J Am Coll Cardiol 2007; 49 : 1071-8.
16. Brandt I, Lambeir AM, Ketelslegers JM, Vanderheyden M, Scharpé S, De Meester I. Dipeptidyl-peptidase IV converts intact B-type natriuretic peptide into its des-SerPro form. Clin Chem 2006; 52 : 82-7.
17. Pankow K, Wang Y, Gembardt F, Krause E, Sun X, Krause G, et al. Successive action of meprin A and neprilysin catabolizes B-type natriuretic peptide. Circ Res 2007; 26 (101) : 875-82.
18. Ala-Kopsala M, Magga J, Peuhkurinen K, Leipälä J, Ruskoaho H, Leppäluoto J, et al. Molecular heterogeneity has a major impact on the measurement of circulating N-terminal fragments of A- and B-type natriuretic peptides. Clin Chem 2004; 50 : 1576-88.
19. Luckenbill KN, Christenson RH, Jaffe AS, Mair J, Ordonez-Llanos J, Pagani F, et al. Cross-reactivity of BNP, NT-proBNP, and proBNP in commercial BNP and NT-proBNP assays : preliminary observations from the IFCC Committee for standardization of markers of cardiac damage. Clin Chem 2008; 54 : 619-21.
20. Ruppé E, Aubert C, Capeau J, Lefèvre G. Dosage du BNP et du NTproBNP : influence de l'étape pré-analytique. Immunoanal Biol Spec 2005; 20 : 78-85.
21. Cauliez B, Berthe MC, Lavoinne A. Le BNP : aspects physiologiques, biologiques et cliniques. Ann Biol Clin (Paris) 2005; 63 : 15-25.
22. Apple FS, Panteghini M, Ravkilde J, Mair J, Wu AH, Tate J, et al. Committee on standardization of markers of cardiac damage of the IFCC. Quality specifications for B-type natriuretic peptide assays. Clin Chem 2005; 51 : 486-93.
23. Shimizu H, Aono K, Masuta K. Degradation of human brain natriuretic peptide (BNP) by contact activation of blood coagulation system. Clin Chim Acta 2001; 305 : 181-6.
24. Shimizu H, Aono K, Masuta K, Asada H, Misaki A, Teraoka H. Stability of brain natriuretic peptide (BNP) in human blood samples. Clin Chim Acta 1999; 285 : 169-72.
25. Yeo KT, Wu AH, Apple FS. Multicenter evaluation of the Roche NT-proBNP assay and comparison to the Biosite Triage BNP assay. Clin Chim Acta 2003; 338 : 107-15.
26. Rawlings ML, Owen WE, Roberts WL. Performance characteristics of four automated natriuretic peptide assays. Am J Clin Pathol 2005; 123 : 439-45.
27. Collinson PO, Barnes SC, Gaze DC. Analytical performance of the N terminal pro B type natriuretic peptide (NT-proBNP) assay on the Elecsys 1010 and 2010 analysers. Eur J Heart Fail 2004; 15 : 365-8.
28. Benoit MO, Dautezac F, Taccoen M, Paul J-L. Évaluation des performances analytiques du dosage du NT-proBNP sur automate d'immunoanalyse Dimension® RxL-HM (Dade Behring). Ann Biol Clin (Paris) 2005; 63 : 411-6.
29. Clerico A, Prontera C, Emdin M, Passino C, Storti S, Poletti R, et al. Analytical performance and diagnostic accuracy of immunometric assays for the measurement of plasma B-type Natriuretic Peptide (BNP) and N-Terminal proBNP. Clin Chem 2005; 51 : 445-7.
30. Goetze JP. Biochemistry of pro-B-type natriuretic peptide-derived peptides : the endocrine heart revisited. Clin Chem 2004; 50 : 1503-10.
31. Prontera C, Storti S, Emdin M. Comparison of a fully automated immunoassay with a point-of-care testing method for B-type natriuretic peptide. Clin Chem 2005; 51 : 1274-6.
32. Mehra MR, Uber PA, Park MH, Scott RL, Ventura HO, Harris BC, et al. Obesity and suppressed B-type natriuretic peptide levels in heart failure. J Am Coll Cardiol 2004; 43 : 1590-5.
33. Wang TJ, Larson MG, Levy D, Benjamin EJ, Leip EP, Wilson PW, et al. Impact of obesity on plasma natriuretic peptide levels. Circulation 2004; 109 : 594-600.
34. Bayes-Genis A, DeFilippi C, Januzzi JL. Understanding aminoterminal pro-B-type natriuretic peptide in obesity. Am J Cardiol 2008; 101 : 89-94.
35. Schou M, Gustafsson F, Kistorp CN, Corell P, Kjaer A, Hildebrandt PR. Effects of body mass index and age on N-terminal pro brain natriuretic peptide are associated with glomerular filtration rate in chronic heart failure patients. Clin Chem 2007; 53 : 1928-35.
36. Bayes-Genis A, Lloyd-Jones DM, van Kimmenade RR, Lainchbury JG, Richards AM, Ordoñez-Llanos J, et al. Effect of body mass index on diagnostic and prognostic usefulness of amino-terminal probrain natriuretic peptide in patients with acute dyspnea. Arch Intern Med 2007; 167 : 400-7.
37. Goetze JP, Jensen G, Møller S, Bendtsen F, Rehfeld JF, Henriksen JH. BNP and N-terminal proBNP are both extracted in the normal kidney. Eur J Clin Invest 2006; 36 : 8-15.
38. Schou M, Dalsgaard MK, Clemmesen O, Dawson EA, Yoshiga CC, Nielsen HB, et al. Kidneys extract BNP and NT-proBNP in healthy young men. J Appl Physiol 2005; 99 : 1676-80.
39. McCullough PA, Duc P, Omland T, McCord J, Nowak RM, Hollander J, et al. Breathing Not Properly Multinational Study Investigators. B-type natriuretic peptide and renal function in the diagnosis of heart failure : an analysis from the Breathing Not Properly Multinational Study. Am J Kidney Dis 2003; 41 : 571-9.
40. Luchner A, Hengstenberg C, Löwel H, Trawinski J, Baumann M, Riegger GA, et al. N-terminal pro-brain natriuretic peptide after myocardial infarction : a marker of cardio-renal function. Hypertension 2002; 39 : 99-104.
41. Mueller C, Laule-Kilian K, Scholer A, Nusbaumer C, Zeller T, Staub D, et al. B-type natriuretic peptide for acute dyspnea in patients with kidney disease : insights from a randomized comparison. Kidney Int 2005; 67 : 278-84.
42. Anwaruddin S, Lloyd-Jones DM, Baggish A, Chen A, Krauser D, Tung R, et al. Renal function, congestive heart failure, and amino-terminal pro-brain natriuretic peptide measurement : results from the ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) Study. J Am Coll Cardiol 2006; 47 : 91-7. (Pubitemid 43005170)
43. De Filippi CR, Fink JC, Nass CM. N-terminal pro-brain natriuretic peptide for predicting coronary disease and left ventricular hypertrophy in asymptomatic CKD not requiring dialysis. Am J Kidney Dis 2005; 46 : 35-44.
44. van Kimmenade RR, Januzzi Jr. JL, Baggish AL, Lainchbury JG, Bayes-Genis A, Richards AM, et al. Amino-terminal pro-brain natriuretic Peptide, renal function, and outcomes in acute heart failure : redefining the cardiorenal interaction? J Am Coll Cardiol 2006; 48 : 1621-7. (Pubitemid 44528169)
45. Chenevier-Gobeaux C, Claessens YE, Voyer S, Desmoulins D, Ekindjian OG. Influence of renal function on N-terminal pro-brain natriuretic peptide (NT-proBNP) in patients admitted for dyspnoea in the Emergency Department : comparison with brain natriuretic peptide (BNP). Clin Chim Acta 2005; 361 : 167-75. (Pubitemid 41382620)
46. Cowie M, Struthers A, Wood D. Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care. Lancet 1997; 350 : 1347-51.
47. Davis M, Espiner E, Richards G. Plasma brain natriuretic peptide in assessment of acute dyspnoea. Lancet 1994; 343 : 440-4.
48. Januzzi Jr. JL, Camargo CA, Anwaruddin S, Baggish AL, Chen AA, Krauser DG, et al. The N-terminal Pro-BNP investigation of dyspnea in the emergency department (PRIDE) study. Am J Cardiol 2005; 95 : 948-54.
49. Januzzi JL, van Kimmenade R, Lainchbury J, Bayes-Genis A, Ordonez-Llanos J, Santalo-Bel M, et al. NT-proBNP testing for diagnosis and short-term prognosis in acute destabilized heart failure : an international pooled analysis of 1256 patients : the International Collaborative of NTproBNP Study. Eur Heart J 2006; 27 : 330-7.
50. Van Kimmenade RR, Pinto YM, Bayes-Genis A, Lainchbury JG, Richards AM, Januzzi Jr. JL. Usefulness of intermediate amino-terminal pro-brain natriuretic peptide concentrations for diagnosis and prognosis of acute heart failure. Am J Cardiol 2006; 98 : 386-90. (Pubitemid 44062449)
51. Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJ, Ponikowsk P, Poole-Wilson PA, et al. Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008 : the task force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European society of cardiology. Eur Heart J 2008; 29 : 2388-442.
52. Remme WJ, Swedberg K. ESC Guidelines : Guidelines for the diagnosis and treatment of chronic heart failure. Eur Heart J 2001; 22 : 1527-60.
53. Cataliotti A, Malatino LS, Jougasaki M, Zoccali C, Castellino P, Giacone G, et al. Circulating natriuretic peptide concentrations in patients with end-stage renal disease : role of brain natriuretic peptide as a biomarker for ventricular remodeling. Mayo Clin Proc 2001; 76 : 1111-9.
54. Logeart D, Saudubray C, Beyne P, Thabut G, Ennezat PV, Chavelas C, et al. Comparative value of Doppler echocardiography and B-type natriuretic peptide assay in the etiologic diagnosis of acute dyspnea. J Am Coll Cardiol 2002; 40 : 1794-800.
55. Nielsen LS, Svanegaard J, Klitgaard NA, Egeblad H. N-terminal pro-brain natriuretic peptide for discriminating between cardiac and non-cardiac dyspnoea. Eur J Heart Fail 2004; 6 : 63-70.
56. Tang WH, Girod JP, Lee MJ. Plasma B-type natriuretic peptide levels in ambulatory patients with established chronic symptomatic systolic heart failure. Circulation 2003; 108 : 2964-9.
57. Gustafsson F, Badskjaer J, Hansen FS, Poulsen AH, Hildebrant P. Value of N-terminal proBNP in the diagnosis of left ventricular systolic dysfunction in primary care patients referred for echocardiography. Heart Drug 2003; 3 : 141-6.
58. Mueller T, Gegenhuber A, Poelz W, Haltmayer M. Head-to-head comparison of the diagnostic utility of BNP and NT-proBNP in symptomatic and asymptomatic structural heart disease. Clin Chim Acta 2004; 341 : 41-8.
59. Prontera C, Emdin M, Zucchelli GC, Ripoli A, Passino C, Clerico A. Analytical performance and diagnostic accuracy of a fully-automated electrochemiluminescent assay for the N-terminal fragment of the propeptide of brain natriuretic peptide in patients with cardiomyopathy : comparison with immunoradiometric assay methods for brain natriuretic peptide and atrial natriuretic peptide. Clin Chem Lab Med 2004; 42 : 37-44.
60. Mc Donagh T, Robb S, Murdoch D. Biochemical detection of left ventricular systolic dysfunction. Lancet 1998; 351 : 9-13. (Pubitemid 28020159)
61. McDonagh TA, Holmer S, Raymond I, Luchner A, Hildebrant P, Dargie HJ. NT-proBNP and the diagnosis of heart failure : a pooled analysis of three European epidemiological studies. Eur J Heart Fail 2004; 6 : 269-73.
62. Gaede P, Hildebrandt P, Parving HH. NT-proBNP as a major risk marker for cardiovascular disease in patietns with type 2diabetes and microalbuminuria plasma. Diabetologia 2005; 48 : 156-63.
63. Kouloubinis A, Kaklamanis L, Ziras N, Sofroniadou S, Makaritsis K, Adamopoulos S, et al. ProANP and NT-proBNP levels to prospectively assess cardiac function in breast cancer patients treated with cardiotoxic chemotherapy. Int J Cardiol 2007; 122 : 195-201.
64. Daugaard G, Lassen U, Bie P, Pedersen EB, Jensen KT, Abildgaard U, et al. Natriuretic peptides in the monitoring of anthracycline induced reduction in left ventricular ejection fraction. Eur J Heart Fail 2005; 7 : 87-93.
65. Sandri MT, Salvatici M, Cardinale D, Zorzino L, PasserinI R, Lentati P, et al. N-terminal pro-B-type natriuretic peptide after high-dose chemotherapy : a marker predictive of cardiac dysfunction? Clin Chem 2005; 51 : 1405-10.
66. Horacek JM, Pudil R, Jebavy L, Tichy M, Zak P, Maly J. Assessment of anthracycline-induced cardiotoxicity with biochemical markers. Exp Oncol 2007; 29 : 309-13.
67. Binder L, Pieske B, Olschewski M, Geibel A, Klostermann B, Reiner C, et al. N-Terminal Pro-Brain natriuretic peptide or troponin testing followed by echocardiography for risk stratification of acute pulmonary embolism. Circulation 2005; 112 : 1573-9.
68. Baixas C, Pathak A, Mucke F, et al. BNP and NT-proBNP as new markers of cardiac dysfunction in patients with shock. Circulation 2003; 108 [Iv-317 (abst 1494)].
69. Roch A, Allardet-Servent J, Michelet P, Oddoze C, Forel JM, Barrau K, et al. NH2 terminal pro-brain natriuretic peptide plasma level as an early marker of prognosis and cardiac dysfunction in septic shock patients. Crit Care Med 2005; 33 : 1001-7.
70. Nagaya N, Nishikimi T, Uematsu M, Satoh T, Kyotani S, Sakamaki F, et al. Plasma brain natriuretic peptide as a prognostic indicator in patients with primary pulmonary hypertension. J Cardiol 2001; 37 : 110-1.
71. Leuchte HH, Holzapfel M, Baumgartner RA, Ding I, Neurohr C, Vogeser M, et al. Clinical significance of brain natriuretic peptide in primary pulmonary hypertension. J Am Coll Cardiol 2004; 43 : 764-70. (Pubitemid 38296473)
72. Tsutamoto T, Wada A, Maeda K, Hisanaga T, Mabuchi N, Hayashi M, et al. Plasma brain natriuretic peptide level as a biochemical marker of morbidity and mortality in patients with asymptomatic or minimally symptomatic left ventricular dysfunction. Comparison with plasma angiotensin II and endothelin-1. Eur Heart J 1999; 20 : 1799-807.
73. Stanek B, Frey B, Hülsmann M, Berger R, Sturm B, Strametz-Juranek J, et al. Prognostic evaluation of neurohumoral plasma levels before and during beta-blocker therapy in advanced left ventricular dysfunction. J Am Coll Cardiol 2001; 38 : 436-42.
74. Latini R, Masson S, Anand I, Salio M, Hester A, Judd D, et al. For the Val-HeFT Investigators. The comparative prognostic value of plasma neurohormones at baseline in patients with heart failure enrolled in Val-HeFT. Eur Heart J 2004; 25 : 292-9.
75. Koglin J, Pehlivanli S, Schwaiblmair M, Vogeser M, Cremer P, von-Scheidt W. Role of brain natriuretic peptide in risk stratification of patients with congestive heart failure. J Am Coll Cardiol 2001; 38 : 1934-41.
76. Gardner RS, Ozalp F, Murday AJ, Robb SD, McDonagh TA. N-terminal pro-brain natriuretic peptide. A new gold standard in predicting mortality in patients with advanced heart failure. Eur Heart J 2003; 24 : 1735-43.
77. Fischer C, Berry C, Blue L, Morton JJ, McMurray J. N-terminal pro-B type natriuretic peptide, but not the new putative cardiac hormone relaxin, predicts prognosis in patients with chronic heart failure. Heart 2003; 89 : 879-81.
78. Kirk V, Bay M, Parner J, Krogsgaard K, Herzog TM, Boesgaard S, et al. N-terminal proBNP and mortality in hospitalised patients with heart failure and preserved vs. reduced systolic function : data from the prospective Copenhagen Hospital Heart Failure Study (CHHF). Eur J Heart Fail 2004; 6 : 335-41.
79. O'Brien RJ, Squire IB, Demme B, Davies JE, Ng LL. Pre-discharge, but not admission, levels of NT-proBNP predict adverse prognosis following acute LVF. Eur J Heart Fail 2003; 5 : 499-506.
80. Bayés-Genís A, Santaló-Bel M, Zapico-Muñiz E, López L, Cotes C, Bellido J, et al. N-terminal probrain natriuretic peptide (NT-proBNP) in the emergency diagnosis and in-hospital monitoring of patients with dyspnoea and ventricular dysfunction. Eur J Heart Fail 2004; 6 : 301-8.
81. Bayes-Genis A, Pascual-Figal D, Fabregat J, Domingo M, Planas F, Casas T, et al. Serial NT-proBNP monitoring and outcomes in outpatients with decompensation of heart failure. Int J Cardiol 2007; 120 : 338-43.
82. Rautureau Y, Baxter GF. Acute actions of natriuretic peptides in coronary vasculature and ischaemic myocardium. Curr Pharm Des 2004; 10 : 2477-82.
83. Galvani M, Ferrini D, Ottani F. Natriuretic peptides for risk stratification of patients with acute coronary syndromes. Eur J Heart Fail 2004; 6 : 327-33.
84. James SK, Lindahl B, Siegbahn A, Stridsberg M, Venge P, Armstrong P, et al. N-terminal pro-brain natriuretic peptide and other risk markers for the separate prediction of mortality and subsequent myocardial infarction in patients with unstable coronary artery disease : a Global Utilization of Strategies To Open occluded arteries (GUSTO)-IV substudy. Circulation 2003; 108 : 275-81.
85. James SK, Lindahl B, Siegbahn A, Stridsberg M;, Venge P, Armstrong P, et al. N-terminal pro-brain natriuretic peptide and other risk markers for the separate prediction of mortality and subsequent myocardial infarction in patients with unstable coronary artery disease : a Global Utilization of Strategies To Open occluded arteries (GUSTO)-IV substudy. Circulation 2003; 108 : 275-81.
86. Ndrepepa G, Braun S, Mehilli J, Niemöller K, Schömig A, Kastrati A. A prospective cohort study of prognostic power of N-terminal probrain natriuretic peptide in patients with non-ST segment elevation acute coronary syndromes. Clin Res Cardiol 2007; 96 : 30-7.
87. Bibbins-Domingo K, Gupta R, Na B, Wu AH, Schiller NB, Whooley MA. N-terminal fragment of the prohormone brain-type natriuretic peptide (NT-proBNP), cardiovascular events, and mortality in patients with stable coronary heart disease. JAMA 2007; 297 : 169-76.
88. Talwar S, Squire IB, Downie PF, Mccullough AM, Campton MC, Davies JE, et al. Profile of plasma N-terminal proBNP following acute myocardial infarction; correlation with left ventricular systolic dysfunction. Eur Heart J 2000; 21 : 1514-21.
89. Bettencourt P. NT-proBNP and BNP : biomarkers for heart failure management. Eur J Heart Fail 2004; 6 : 359-63.
90. Miller WL, Hartman KA, Burritt MF, Borgeson DD, Burnett Jr. JC, Jaffe AS. Biomarker responses during and after treatment with nesiritide infusion in patients with decompensated chronic heart failure. Clin Chem 2005; 51 : 569-77.
91. Gegenhuber A. Time course of BNP and NT-proBNP changes in patients with decompensated heart failure. Clin Chem 2004; 50 : 454-6.
92. Wu AH, Smith A. Biological variation of the natriuretic peptides and their role in monitoring patients with heart failure. Eur J Heart Fail 2004; 6 : 355-8.
93. Troughton RW, Rampton CM, Yandle TG. Treatment of heart failure guided by plasma amino terminal brain natriuretic peptide concentration. Lancet 2000; 355 : 1126-30.
94. Lainchbury JG, Troughton RW, Frampton CM, Yandle TG, Hamid A, Nicholls MG, et al. NTproBNP-guided drug treatment for chronic heart failure : design and methods in the "BATTLESCARRED" trial. Eur J Heart Fail 2006; 8 : 532-8.
95. Rajagopalan S, Croal BL, Bachoo P, Hillis GS, Cuthbertson BH, Brittenden J. N-terminal pro B-type natriuretic peptide is an independent predictor of postoperative myocardial injury in patients undergoing major vascular surgery. J Vasc Surg 2008; 48 : 912-7.
96. Yeh HM, Lau HP, Lin JM, Sun WZ, Wang MJ, Lai LP. Preoperative plasma N-terminal pro-brain natriuretic peptide as a marker of cardiac risk in patients undergoing elective non-cardiac surgery. Br J Surg 2005; 92 : 1041-5.
97. Feringa HH, Bax JJ, Elhendy A, de Jonge R, Lindemans J, Schouten O, et al. Association of plasma N-terminal pro-B-type natriuretic peptide with postoperative cardiac events in patients undergoing surgery for abdominal aortic aneurysm or leg bypass. Am J Cardiol 2006; 98 : 111-5.
98. Siebert U, Januzzi Jr. JL, Beinfeld MT, Cameron R, Gazelle GS. Cost-effectiveness of using N-terminal pro-brain natriuretic peptide to guide the diagnostic assessment and management of dyspneic patients in the emergency department. Am J Cardiol 2006; 98 : 800-5.
99. Moe GW, Howlett J, Januzzi JL, Zowall H, Canadian Multicenter Improved Management of Patients With Congestive Heart Failure (IMPROVE-CHF) Study Investigators. N-terminal pro-B-type natriuretic peptide testing improves the management of patients with suspected acute heart failure : primary results of the Canadian prospective randomized multicenter IMPROVE-CHF study. Circulation 2007; 115 : 3103-10.